Summary of the technology
Triple negative breast cancers are tipically associated with por prognosis, due to aggressive tumor phenotype(s), only partial response to chemoterapy and present lack of clinically established targeted therapies and respresent the focus of increasing interest at the clinical, biological and epidemiological level, as disclosed in Podo et al., Triple –negative breast cancer: Present challenges and new perspectives, Mol. Oncol., 2010, 4, 209-229.
There is, thus, a particular need for new active agents suitable for breast cancer treatment, and in particular need for triple negative breast cancers.
Description of the technology
The present invention relates to a new use of zonisamide, namely to zonisamide for use in the treatment breast cancer, in particular triple negative breast cancer tumours. It relates also to a pharmaceutical composition comprising zonisamide and at least one pharmaceutically acceptable excipient or vehicle, for use in the treatment of breast cancer.
The zonisamide inhibits the LOXL2-enzymatic activity, and consequently opens a therapeutic window for the treatment of breast cancer, in particular triple negative breast cancer.
Main advantages of its use
- Zonisamide has been identified as LOXL2 inhibitor by a drug-repurposing approach. It is already used in human treatments.It’s a generic compound.
- The technology aims the pharma industry dealing with breast cáncer treatment.